Thyrocare Technologies Limited — Investor Meet, 27-07-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Thyrocare delivered a strong Q1 FY27, with consolidated revenue up 24.3% YoY to 240 Cr and PAT rising 34% to 51.3 Cr. Pathology grew 26%, driven by 27% franchisee and 26% partnership business growth. Gross margins expanded to 74.1%. Management is actively divesting the non-strategic radiology business and focusing on the new specialty diagnostics segment (allergy, genomics), aiming for 15-20% of its portfolio in 3-5 years. The company continues its core strategy of providing affordable, quality diagnostics, expanding its 11,700-strong franchisee network and 44 labs while maintaining strong operational efficiency. This reflects a focused growth trajectory.